Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02362997 · ClinicalTrials.gov registry record · Phase 2

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

A Phase 2 study of Diffuse Large B Cell Lymphoma and Hodgkin Lymphoma, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
Phase 2
Development phase
82
Enrollment target
6
Study locations

NCT02362997 is a Phase 2 study of Diffuse Large B Cell Lymphoma and Hodgkin Lymphoma that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 82 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (62% lower). The trial reports 6 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02362997, a Phase 2 study of Diffuse Large B Cell Lymphoma and Hodgkin Lymphoma, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
Phase 2
Development phase
82 participants
Enrollment target
6
Study locations

Study Summary

This phase II study is designed to determine the clinical efficacy of PD-1 blockade, using the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475), administered as consolidation therapy after autologous stem cell transplant (ASCT), in patients with relapsed or refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL), classical Hodgkin Lymphoma (cHL) or peripheral T-cell lymphoma (PTCL) in 1st remission.

Conditions Studied

Diffuse Large B Cell Lymphoma Hodgkin Lymphoma Peripheral T-Cell Lymphoma

Interventions

  • DRUG Pembrolizumab

Study Locations (6)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Beth Israel Deaconess Medical Center - Boston
  • Dana Farber Cancer Institute - Boston

California

  • City of Hope National Medical Center - Duarte

New York

  • Memorial Sloan Kettering Cancer Center - New York

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 82 participants
Start Date 2015-04
Est. Completion 2023-06
Phase Phase 2

Sponsor

Dana-Farber Cancer Institute

781 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02362997

The ClinicalTrials.gov registry entry for NCT02362997 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (62% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.

NCT02362997 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, California, New York.

Frequently Asked Questions

What is clinical trial NCT02362997 about?

NCT02362997 is a clinical study titled "Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL". This phase II study is designed to determine the clinical efficacy of PD-1 blockade, using the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475), administered as consolidation therapy after autologous stem cell transplant (ASCT), in patients with relapsed or refractory (R/R) Diffuse Large B Cell...

What is the current status of trial NCT02362997?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2015-04. Estimated completion is 2023-06.

What conditions does trial NCT02362997 study?

This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma, Hodgkin Lymphoma, Peripheral T-Cell Lymphoma.

What interventions are being tested in trial NCT02362997?

The interventions under investigation include: Pembrolizumab (DRUG).

Who is sponsoring clinical trial NCT02362997?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02362997 being conducted?

This trial has 6 study locations across California, Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diffuse Large B Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diffuse Large B Cell Lymphoma

All registered trials for this condition

Hodgkin Lymphoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.